ACY-241Selective and orally active HDAC6 inhibitor CAS# 1316215-12-9 |
- VX-222 (VCH-222, Lomibuvir)
Catalog No.:BCC2108
CAS No.:1026785-59-0
- CHM 1
Catalog No.:BCC2387
CAS No.:154554-41-3
- T 705
Catalog No.:BCC4130
CAS No.:259793-96-9
- Gambogic acid
Catalog No.:BCN2318
CAS No.:2752-65-0
- Fidaxomicin
Catalog No.:BCC4660
CAS No.:873857-62-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1316215-12-9 | SDF | Download SDF |
PubChem ID | 53340426 | Appearance | Powder |
Formula | C24H26ClN5O3 | M.Wt | 467.95 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | ACY241 | ||
Solubility | DMSO : ≥ 30 mg/mL (64.11 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide | ||
SMILES | C1=CC=C(C=C1)N(C2=CC=CC=C2Cl)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO | ||
Standard InChIKey | VLIUIBXPEDFJRF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H26ClN5O3/c25-20-12-7-8-13-21(20)30(19-10-4-3-5-11-19)24-27-16-18(17-28-24)23(32)26-15-9-2-1-6-14-22(31)29-33/h3-5,7-8,10-13,16-17,33H,1-2,6,9,14-15H2,(H,26,32)(H,29,31) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Citarinostat is a HDAC6 specific inhibitor, with IC50 of 4 nM and 76 nM for HDAC6 and HDAC3, respectively.
IC50 value: 4 nM (HDAC6), 76 nM (HDAC3)
Target: HDAC
The detailed information please refer to WO2015061684A1 and 2015054197A1. References: |
ACY-241 Dilution Calculator
ACY-241 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.137 mL | 10.6849 mL | 21.3698 mL | 42.7396 mL | 53.4245 mL |
5 mM | 0.4274 mL | 2.137 mL | 4.274 mL | 8.5479 mL | 10.6849 mL |
10 mM | 0.2137 mL | 1.0685 mL | 2.137 mL | 4.274 mL | 5.3425 mL |
50 mM | 0.0427 mL | 0.2137 mL | 0.4274 mL | 0.8548 mL | 1.0685 mL |
100 mM | 0.0214 mL | 0.1068 mL | 0.2137 mL | 0.4274 mL | 0.5342 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ACY-241 is a new, selective and orally available inhibitor of HDAC6 [1][2].
Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from an ε-N-acetyl lysine on a histone, allowing the histones to wrap the DNA more tightly. HDAC6 plays an important role in transcriptional regulation and cell cycle progression.
ACY-241 is a new, selective and orally available HDAC6 inhibitor. In MM and MCL cells, the addition of ACY-241 to either lenalidomide (len) or pomalidomide (pom) resulted in synergistic increases in apoptosis and further reduced the expression of transcription factors MYC and IRF4 [1]. In multiple solid tumor cell lines, combination treatment with ACY-241 and paclitaxel resulted in enhanced inhibition of cell proliferation and increased cell death, compared with either single agent alone [2].
In MM xenograft model, combination treatment with ACY-241 and pomalidomide was well tolerated with no overt toxicity and significantly extended survival [1]. In xenograft models of pancreatic and ovarian cancer, combination treatment with ACY-241 and paclitaxel significantly increased mitotic cells with multipolar spindles. ACY-241 dose-dependently increased α-tubulin hyperacetylation [2].
References:
[1]. Quayle SN, Almeciga-Pinto I, Tamang D, et al. Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015, Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5380.
[2]. Huang P, Almeciga-Pinto I, Jordan M, et al. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. In: Proceedings of the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, Massachusetts. Philadelphia (PA): AACR
- Rocilinostat (ACY-1215)
Catalog No.:BCC2144
CAS No.:1316214-52-4
- (+)-Pteryxin
Catalog No.:BCN3470
CAS No.:13161-75-6
- Amyloid Beta-peptide (25-35) (human)
Catalog No.:BCC1027
CAS No.:131602-53-4
- Betulinaldehyde
Catalog No.:BCN1249
CAS No.:13159-28-9
- Calystegine A3
Catalog No.:BCN1884
CAS No.:131580-36-4
- Camelliaside B
Catalog No.:BCN3872
CAS No.:131573-90-5
- Triumbelletin
Catalog No.:BCN6779
CAS No.:131559-54-1
- VU 591 hydrochloride
Catalog No.:BCC6126
CAS No.:1315380-70-1
- NPEC-caged-(1S,3R)-ACPD
Catalog No.:BCC7653
CAS No.:1315379-60-2
- Rac1 Inhibitor F56, control peptide
Catalog No.:BCC5887
CAS No.:1315378-77-8
- pep2-SVKE
Catalog No.:BCC5785
CAS No.:1315378-76-7
- MNI caged kainic acid
Catalog No.:BCC7297
CAS No.:1315378-75-6
- OPC 21268
Catalog No.:BCC7812
CAS No.:131631-89-5
- Chalepensin
Catalog No.:BCN7334
CAS No.:13164-03-9
- Turmeronol A
Catalog No.:BCN6777
CAS No.:131651-37-1
- 8-(1-Chloro-2-hydroxy-3-methylbut-3-enyl)-7-methoxycoumarin
Catalog No.:BCN7058
CAS No.:131652-35-2
- Parsonsianine
Catalog No.:BCN2110
CAS No.:131683-36-8
- (R)-(-)-4-Benzyl-3-propionyl-2-oxazolidinone
Catalog No.:BCC8392
CAS No.:131685-53-5
- Arbidol HCl
Catalog No.:BCC3722
CAS No.:131707-23-8
- Urolignoside
Catalog No.:BCN6758
CAS No.:131723-83-6
- Flavopiridol hydrochloride
Catalog No.:BCC3925
CAS No.:131740-09-5
- DAU 5884 hydrochloride
Catalog No.:BCC7263
CAS No.:131780-48-8
- Ugaxanthone
Catalog No.:BCN6775
CAS No.:13179-11-8
- Cardenolide B-1
Catalog No.:BCN4714
CAS No.:1318158-89-2
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.[Pubmed:27926524]
Oncotarget. 2017 Jan 10;8(2):2694-2707.
ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness. We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth. In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone. Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells. At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and gamma-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification. The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.[Pubmed:28264055]
PLoS One. 2017 Mar 6;12(3):e0173507.
Thalidomide-based Immunomodulatory Drugs (IMiDs(R)), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, alphaCD38 monoclonal antibodies, as well as histone deacetylase (HDAC) inhibitors for combination therapy. HDAC inhibitors broadly targeting Class I and IIb HDACs have shown potent preclinical efficacy but have frequently demonstrated an undesirable safety profile in combination therapy approaches in clinical studies. Therefore, development of more selective HDAC inhibitors could provide enhanced efficacy with reduced side effects in combination with IMiDs(R) for the treatment of B-cell malignancies, including multiple myeloma. Here, the second generation selective HDAC6 inhibitor citarinostat (ACY-241), with a more favorable safety profile than non-selective pan-HDAC inhibitors, is shown to synergize with pomalidomide in in vitro assays through promoting greater apoptosis and cell cycle arrest. Furthermore, utilizing a multiple myeloma in vivo murine xenograft model, combination treatment with pomalidomide and ACY-241 leads to increased tumor growth inhibition. At the molecular level, combination treatment with ACY-241 and pomalidomide leads to greater suppression of the pro-survival factors survivin, Myc, and IRF4. The results presented here demonstrate synergy between pomalidomide and ACY-241 in both in vitro and in vivo preclinical models, providing further impetus for clinical development of ACY-241 for use in combination with IMiDs for patients with multiple myeloma and potentially other B-cell malignancies.